January 6th 2025
Sanofi and SK bioscience expand collaboration on pneumococcal conjugate vaccines, including a 21-valent candidate for pediatric populations.
October 30th 2024
Your daily dose of the clinical news you may have missed.
October 24th 2024
The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.
September 20th 2024
New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.
July 1st 2024
The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.